Abstract
Paratesticular serous papillary carcinomas are very rare, with less than 40 cases reported in the literature. These neoplasms are Müllerian in origin, and more commonly seen as epithelial-type ovarian cancer. Given the rarity of this tumor in men, staging and recommended treatment options do not exist. Herein, we present the case of a 35-year-old male with high-grade invasive serous papillary carcinoma. He was diagnosed after left radical orchiectomy for paratesticular mass and subsequently treated with adjuvant chemotherapy according to existing recommendations for its ovarian counterpart. Chemotherapy was well tolerated and surveillance imaging has shown no evidence of disease. This case suggests a potential role for adjuvant therapy in patients with high-grade paratesticular serous papillary carcinoma.
Highlights
Received 08/29/2017 Review began 10/05/2017 Review ended 02/08/2018 Published 02/13/2018Testicular cancer represents one of the most common malignancies in young men in the United States
We present the case of a 35-year-old male with invasive, nonmetastatic high-grade serous papillary carcinoma treated with radical orchiectomy and adjuvant chemotherapy
Müllerian-derived serous papillary carcinoma is a rare malignancy in males and its origin is not fully understood
Summary
Received 08/29/2017 Review began 10/05/2017 Review ended 02/08/2018 Published 02/13/2018. Several unusual non-germ cell subtypes have been reported in the literature, including serous papillary carcinoma [2] The majority of these cases have been treated primarily with orchiectomy, with final pathology showing either low-grade or borderline histology [3]. After his final round of chemotherapy, the patient was deemed to be disease-free, supported by a negative CT scan of the chest, abdomen, and pelvis. As of his most recent follow-up appointment three months after his last treatment, the patient continues to do well with no evidence of disease on imaging and a serum CA-125 level of 14.1 U/mL (Reference range 0-35 U/L)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
